Literature DB >> 10661822

Axillofemoral bypass operations in Kuopio University Hospital 1985-1996.

T Jämsén1, H Tulla, P Loponen.   

Abstract

BACKGROUND AND AIMS: Axillofemoral bypass has been used since the 1960's in poor-risk patients with aortoiliac atherosclerotic occlusive disease to improve arterial circulation in the lower extremities. This article describes the outcome of 84 consecutive operations in our hospital.
MATERIAL AND METHODS: During the period 1.1.1985-31.5.1996, 84 axillofemoral bypass operations were performed in our hospital. In this retrospective study, information was based on patient records and clinical follow-up examination for surviving patients living in the area of Kuopio province and operated before the end of 1995. Patencies and survivals were established using the life table method.
RESULTS: The primary patency rate was 81.1 % at one year, 64.3 % at three years and 56.7 % at five years. The secondary patency rates were 92.1%, 67.1% and 57.7 %, respectively. The operative mortality rate was 6.0%. Eighty-five percent of the patients were alive one year after the operation, compared to 50 % after five years. Serious complications were rare, but local wound complications occurred in 29 %. Vascular reoperations were needed in 29 %, particularly thrombectomies.
CONCLUSIONS: Axillofemoral bypass gives acceptable results in the treatment of lower leg ischaemia in elderly poor-risk patients.

Entities:  

Mesh:

Year:  1999        PMID: 10661822

Source DB:  PubMed          Journal:  Ann Chir Gynaecol        ISSN: 0355-9521


  2 in total

1.  Primary bypass surgery from the descending aorta to the iliac arteries for a severely calcified aorta: report of two cases.

Authors:  Osamu Sato; Hiroyuki Okamoto; Harunobu Matsumoto; Kouji Ogata; Keisuke Kondoh
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  The outcome of the axillofemoral bypass: a retrospective analysis of 45 patients.

Authors:  Marjolein H Liedenbaum; Froukje J Verdam; David Spelt; Hans G W de Groot; Jan van der Waal; Lijckle van der Laan
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.